患者来源类器官药敏检测是胰腺癌精准医疗的临床可行策略
本研究旨在验证患者来源类器官(PDO)指导的精准医疗框架在胰腺癌中的临床可行性。通过多中心联盟从手术标本和内镜活检建立PDO并进行高通量药敏检测,PDO建立成功率为77%,药敏检测中位时间48天(范围18-102天),可在围手术期恢复期内完成,有望指导术后辅助化疗选择。
要点
- PDO从手术标本和内镜活检建立成功率达77%
- 快速药敏检测中位48天,可在围手术期恢复期内完成
- 早期传代保留PDAC克隆异质性,晚期传代显性克隆药敏谱与早期相似
核心结论
- 从接受胰腺癌手术的患者快速建立PDO在围手术期恢复期内完全可行,使药敏检测有望指导术后辅助化疗选择。
研究设计与样本
- 从手术标本和内镜活检建立PDO,在Matrigel中扩增并进行高通量药敏检测,通过细胞活力评估标准方案化疗药的疗效。
主要发现
- 在多机构学术医学中心联盟建立了PDO快速药敏检测框架。
- 远程获取并运送至中央生物样本库的标本保持活力,PDO建立成功率为77%。
- 早期培养保留PDAC中所见的克隆异质性及相似表型(囊性-实性)。
- 晚期培养显示显性克隆,其药敏检测谱与早期传代相似。
临床怎么用
- 对接受胰腺癌手术的患者,可在围手术期恢复期内建立PDO并进行药敏检测,以潜在指导术后辅助化疗方案选择。
局限性
- 验证PDO作为预测性生物标志物的研究仍在进行中。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: PDAC patients who undergo surgical resection and receive effective chemotherapy have the best chance of long-term survival. Unfortunately, we lack predictive biomarkers to guide optimal systemic treatment. Ex-vivo generation of PDO for pharmacotyping may serve as predictive biomarkers in PDAC. The goal of the current study was to demonstrate the clinical feasibility of a PDO-guided precision medicine framework of care. METHODS: PDO cultures were established from surgical specimens and endoscopic biopsies, expanded in Matrigel, and used for high-throughput drug testing (pharmacotyping). Efficacy of standard-of-care chemotherapeutics was assessed by measuring cell viability after drug exposure. RESULTS: A framework for rapid pharmacotyping of PDOs was established across a multi-institutional consortium of academic medical centers. Specimens obtained remotely and shipped to a central biorepository maintain viability and allowed generation of PDOs with 77% success. Early cultures maintain the clonal heterogeneity seen in PDAC with similar phenotypes (cystic-solid). Late cultures exhibit a dominant clone with a pharmacotyping profile similar to early passages. The biomass required for accurate pharmacotyping can be minimized by leveraging a high-throughput technology. Twenty-nine cultures were pharmacotyped to derive a population distribution of chemotherapeutic sensitivity at our center. Pharmacotyping rapidly-expanded PDOs was completed in a median of 48 (range 18-102) days. CONCLUSIONS: Rapid development of PDOs from patients undergoing surgery for PDAC is eminently feasible within the perioperative recovery period, enabling the potential for pharmacotyping to guide postoperative adjuvant chemotherapeutic selection. Studies validating PDOs as a promising predictive biomarker are ongoing.
引用
- Seppälä TT, Zimmerman JW, Sereni E, et al. Patient-derived Organoid Pharmacotyping is a Clinically Tractable Strategy for Precision Medicine in Pancreatic Cancer. Ann Surg. 2020. PMID: 32657929. doi:10.1097/SLA.0000000000004200
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。